CORT
Corcept Therapeutics Incorporated
NASDAQ · USHealthcareBiotechnology
$91.57+1.16%
Price as of Jul 20, 2026
CORT profitability
Corcept Therapeutics Incorporated profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 98.3%
- EBITDA margin
- 1.8%
- EBIT margin
- -1.1%
- Net margin
- 6.2%
- Free cash flow margin
- 15.6%
Returns
- Return on equity
- 7.5%
- Return on assets
- 5.9%
- Return on invested capital
- -1.3%
- Asset turnover
- 0.93x
Cash efficiency
- Cash from operations
- $120.1M
- Cash per share
- $3.15
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.